Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03772587 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis
A Phase 2 study, sponsored by Momenta Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
NCT03772587 is a Phase 2 study that has completed, run by Momenta Pharmaceuticals. The registered enrollment target is 68 participants.
The verdict
NCT03772587, a Phase 2 study, has completed, sponsored by Momenta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of M281 administered to participants with generalized myasthenia gravis (gMG) who have an insufficient clinical response to ongoing standard of care therapy.
Interventions
- OTHER Placebo
- DRUG M281
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2019-04-10 |
| Est. Completion | 2020-06-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03772587
The ClinicalTrials.gov registry entry for NCT03772587 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Momenta Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03772587 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03772587 about?
NCT03772587 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis". The purpose of this study is to evaluate the safety, tolerability, and efficacy of M281 administered to participants with generalized myasthenia gravis (gMG) who have an insufficient clinical response to ongoing standard of care therapy.
What is the current status of trial NCT03772587?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2019-04-10. Estimated completion is 2020-06-25.
What interventions are being tested in trial NCT03772587?
The interventions under investigation include: Placebo (OTHER), M281 (DRUG).
Who is sponsoring clinical trial NCT03772587?
This trial is sponsored by Momenta Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.